Skip to main content

Imjudo

Generic name: tremelimumab-actl
Dosage form: injection
Drug class: Anti-CTLA-4 monoclonal antibodies

Medically reviewed by Carmen Pope, BPharm. Last updated on Jun 2, 2023.

What is Imjudo?

Imjudo is a prescription medicine that may be used in combination with Imfinzi (durvalumab) to treat adults with unresectable hepatocellular carcinoma or non-small cell lung cancer (NSCLC) that has spread (metastatic NSCLC).

Imjudo is a human monoclonal antibody that works by blocking the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4).

What is Imjudo used to treat?

Imjudo is used in combination with durvalumab to treat hepatocellular carcinoma, the most common type of primary liver cancer.

Imjudo may also be used in combination with durvalumab and platinum-based chemotherapy for the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) genomic tumor aberrations.

It is not known if this medicine is safe and effective in children.

Important information

Imjudo in combination with durvalumab can cause your immune system to attack normal organs and tissues in any area of your body and can affect the way they work. These problems can sometimes become severe or life-threatening and can lead to death. You can have more than one of these problems at the same time. These problems may happen anytime during treatment or even after your treatment has ended.

Call or see your healthcare provider right away if you develop any new or worsening signs or symptoms, including:

Lung problems.

Intestinal problems.

Liver problems.

Hormone gland problems.

Kidney problems.

Skin problems.

Pancreas problems.

Problems can also happen in other organs and tissues. These are not all of the signs and symptoms of immune system problems that can happen with Imjudo. Call or see your healthcare provider right away for any new or worsening signs or symptoms, which may include:

Infusion reactions that can sometimes be severe or life-threatening. Signs and symptoms of infusion reactions may include:

Getting medical treatment right away may help keep these problems from becoming more serious.
Your healthcare provider will check you for these problems during your treatment. Your healthcare provider may treat you with corticosteroid or hormone replacement medicines. Your healthcare provider may also need to delay or completely stop treatment if you have severe side effects.

Before you receive Imjudo

Before you receive Imjudo, tell your healthcare provider about all of your medical conditions, including if you:

Females who are able to become pregnant

Tell your healthcare provider right away if you become pregnant or think you may be pregnant during treatment.

What other drugs will affect Imjudo?

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

How will I receive Imjudo?

Dosing information

Usual Adult Dose for Unresectable Hepatocellular Carcinoma

Weight 30 kg and more:
Imjudo 300 mg as a single dose in combination with durvalumab 1,500 mg at Cycle 1/Day 1, followed by durvalumab as a single agent every 4 weeks

Weight less than 30 kg:
Imjudo 4 mg/kg as a single dose in combination with durvalumab 20 mg/kg at Cycle 1/Day 1, followed by durvalumab as a single agent every 4 weeks

Comment:
- Administer Imjudo as an intravenous infusion over 60 minutes after dilution.

Use:
- indicated in combination with durvalumab, for the treatment of adult patients with unresectable hepatocellular carcinoma

Usual Adult Dose for Metastatic NSCLC

Greater than or equal to 30 kg: 75 mg every 3 weeks in combination with durvalumab 1,500 mg and platinum-based chemotherapy for 4 cycles, and then administer durvalumab 1,500 mg every 4 weeks as a single agent with histology-based pemetrexed therapy every 4 weeks, and a fifth dose of Imjudo 75 mg in combination with durvalumab dose 6 at week 16.

30 kg or less: 1 mg/kg every 3 weeks in combination with durvalumab 20 mg/kg and platinum-based chemotherapy for 4 cycles, and then administer durvalumab 20 mg/kg every 4 weeks as a single agent with histology-based pemetrexed therapy every 4 weeks, and a fifth dose of Imjudo 1 mg/kg in combination with durvalumab dose 6 at week 16.

Use:
- the treatment of adult patients with metastatic NSCLC with no sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) genomic tumor aberrations in combination with durvalumab and platinum-based chemotherapy.

Imjudo side effects

Imjudo can cause serious side effects, including:

See Important information

The most common side effects of Imjudo when used in combination with durvalumab include:

Tell your healthcare provider if you have any side effect that bothers you or that does not go away.

These are not all the possible side effects. Ask your healthcare provider or pharmacist for more information.

Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.

General information about the safe and effective use of Imjudo.

Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. If you would like more information, talk with your healthcare provider. You can ask your healthcare provider for information that is written for health professionals.

What are the ingredients in Imjudo?

Active ingredient: tremelimumab-actl
Inactive ingredients: edetate disodium, histidine, L-histidine hydrochloride monohydrate, polysorbate 80, trehalose, and Water for Injection, USP.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.